



---

**FOR IMMEDIATE RELEASE**

---

**Contact:**  
Susan Brady  
Corporate Communications  
617.621.8304  
[sbrady@ironwoodpharma.com](mailto:sbrady@ironwoodpharma.com)

## **IRONWOOD PHARMACEUTICALS TO PRESENT AT CREDIT SUISSE 2011 HEALTHCARE CONFERENCE**

CAMBRIDGE, Mass., November 2, 2011 — [Ironwood Pharmaceuticals, Inc.](http://www.ironwoodpharma.com) (NASDAQ: IRWD) will present at the Credit Suisse 2011 Healthcare Conference on Wednesday, November 9, 2011 at 3:00 p.m. Mountain Time / 5:00 p.m. Eastern Time at the Arizona Biltmore in Phoenix.

A live webcast of Ironwood's presentation will be accessible through the Investors section of the company's website at [www.ironwoodpharma.com](http://www.ironwoodpharma.com). To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Ironwood's website for 14 days following the conference.

### **About Ironwood Pharmaceuticals**

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood's GC-C agonist, is an investigational drug for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). The efficacy portion of linaclotide's development program has been completed and supports the recently submitted NDA submission for both indications, as well as the MAA submission in Europe for the IBS-C indication. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is located in Cambridge, Mass. To learn more, visit [www.ironwoodpharma.com](http://www.ironwoodpharma.com).

*SOURCE: Ironwood Pharmaceuticals, Inc.*